Animal studies showed that cardiac fibrosis and renal dysfunction can be reduced by chymase inhibition, leading to the hypothesis that chymase inhibitors may be beneficial for treatment of heart failure (HF) and chronic kidney disease (CKD) [1, 2]. This evidence concerns the gene CMA1 and chronic kidney disease.